Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C max and impr...
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C max and improved tolerability, in patients with solid tumors
About this item
Full title
Author / Creator
Publisher
United States
Journal title
Language
English
Formats
Publication information
Publisher
United States
Subjects
More information
Scope and Contents
Contents
5-fluorouracil (5-FU) and 5-FU derivatives, such as capecitabine, UFT, and S-1, are the mainstay of chemotherapy treatment for gastrointestinal cancers, and other solid tumors. Compared with other cytotoxic chemotherapies, these drugs generally have a favorable safety profile, but hematologic and gastrointestinal toxicities remain common. DFP-11207...
Alternative Titles
Full title
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C max and improved tolerability, in patients with solid tumors
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_32377978
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_32377978
Other Identifiers
E-ISSN
1573-0646
DOI
10.1007/s10637-020-00939-w
